Peihua Liu1,2, Feizhou Zhu2,3, Minghao Li1, Daud Athanasius Dube4, Qianqian Liu3, Cikui Wang1, Qiao Xiao1, Liang Zhang1, Shuai Gao3, Zhuolin Li3, Bo Zhang1, Jing Liu1, Longfei Liu1,2, Xiang Chen1,2. 1. Department of Urology, Xiangya Hospital, Central South University, Changsha 410008, China. 2. National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha 410008, China. 3. Department of Biochemistry and Molecular Biology, School of Life Sciences, Central South University, Changsha 410013, China. 4. Academic Training Unit of Urological Surgery, College of Health Science, University of Zimbabwe, Harare, Zimbabwe.
Abstract
BACKGROUND: The Von Hippel-Lindau (VHL) p.Tyr98His (Y98H) mutation is designated as the "Black Forest" founder mutation and has been previously reported in Western countries. This study reports the first recorded Chinese VHL family with the "Black Forest" mutation in Asia. METHODS: Paired whole-exome sequencing (WES), Sanger sequencing and immunohistochemistry (IHC) were performed on samples from a large Chinese family to confirm the causative mutation and mutation carriers in the family. Clinical manifestations of the family were summarized and compared with those reported from other patients with the VHL Y98H mutation. RESULTS: The Chinese pheochromocytoma (PCC) family was identified as a VHL type 2 family with a Y98H mutation. There were 4 VHL patients and 11 currently healthy individuals with the mutation. Copy number analysis and SDHB IHC were performed to exclude interference from other pathogenic genes of PCC or paraganglioma (PGL). CONCLUSIONS: We report the first recorded instance of a Chinese VHL type 2 family with the "Black Forest" mutation by using WES and Sanger sequencing, which widens the currently recorded presence of the "Black Forest" mutation to China and potentially elsewhere in Asia and indicates that the "Black Forest" mutation does not uniquely evolve in occidental countries. A personalized surveillance approach, which may be more appropriate for affected families, has been recommended to improve quality of life.
BACKGROUND: The Von Hippel-Lindau (VHL) p.Tyr98His (Y98H) mutation is designated as the "Black Forest" founder mutation and has been previously reported in Western countries. This study reports the first recorded Chinese VHL family with the "Black Forest" mutation in Asia. METHODS: Paired whole-exome sequencing (WES), Sanger sequencing and immunohistochemistry (IHC) were performed on samples from a large Chinese family to confirm the causative mutation and mutation carriers in the family. Clinical manifestations of the family were summarized and compared with those reported from other patients with the VHL Y98H mutation. RESULTS: The Chinese pheochromocytoma (PCC) family was identified as a VHL type 2 family with a Y98H mutation. There were 4 VHL patients and 11 currently healthy individuals with the mutation. Copy number analysis and SDHB IHC were performed to exclude interference from other pathogenic genes of PCC or paraganglioma (PGL). CONCLUSIONS: We report the first recorded instance of a Chinese VHL type 2 family with the "Black Forest" mutation by using WES and Sanger sequencing, which widens the currently recorded presence of the "Black Forest" mutation to China and potentially elsewhere in Asia and indicates that the "Black Forest" mutation does not uniquely evolve in occidental countries. A personalized surveillance approach, which may be more appropriate for affected families, has been recommended to improve quality of life.
Entities:
Keywords:
Black Forest mutation; Von Hippel-Lindau disease (VHL disease); pheochromocytoma (PCC); whole-exome sequencing (WES)
Authors: Hartmut P H Neumann; Birke Bausch; Sarah R McWhinney; Bernhard U Bender; Oliver Gimm; Gerlind Franke; Joerg Schipper; Joachim Klisch; Carsten Altehoefer; Klaus Zerres; Andrzej Januszewicz; Charis Eng; Wendy M Smith; Robin Munk; Tanja Manz; Sven Glaesker; Thomas W Apel; Markus Treier; Martin Reineke; Martin K Walz; Cuong Hoang-Vu; Michael Brauckhoff; Andreas Klein-Franke; Peter Klose; Heinrich Schmidt; Margarete Maier-Woelfle; Mariola Peçzkowska; Cesary Szmigielski; Charis Eng Journal: N Engl J Med Date: 2002-05-09 Impact factor: 91.245
Authors: S Gläsker; B U Bender; T W Apel; E Natt; V van Velthoven; R Scheremet; J Zentner; H P Neumann Journal: J Neurol Neurosurg Psychiatry Date: 1999-12 Impact factor: 10.154
Authors: Alisdair McNeill; Eleanor Rattenberry; Richard Barber; Pip Killick; Fiona MacDonald; Eamonn R Maher Journal: Am J Med Genet A Date: 2009-10 Impact factor: 2.802
Authors: F J Hes; R B van der Luijt; A L W Janssen; R A Zewald; G J de Jong; J W Lenders; T P Links; G P M Luyten; R H Sijmons; H J Eussen; D J J Halley; C J M Lips; P L Pearson; A M W van den Ouweland; D F Majoor-Krakauer Journal: Clin Genet Date: 2007-08 Impact factor: 4.438
Authors: Russell R Lonser; Gladys M Glenn; McClellan Walther; Emily Y Chew; Steven K Libutti; W Marston Linehan; Edward H Oldfield Journal: Lancet Date: 2003-06-14 Impact factor: 79.321
Authors: José Gaal; Francien H van Nederveen; Zoran Erlic; Esther Korpershoek; Rogier Oldenburg; Carsten C Boedeker; Udo Kontny; Hartmut P Neumann; Winand N M Dinjens; Ronald R de Krijger Journal: J Clin Endocrinol Metab Date: 2009-10-06 Impact factor: 5.958
Authors: Carsten C Boedeker; Zoran Erlic; Stéphane Richard; Udo Kontny; Anne-Paule Gimenez-Roqueplo; Alberto Cascon; Mercedes Robledo; José M de Campos; Francien H van Nederveen; Ronald R de Krijger; Nelly Burnichon; José Gaal; Martin A Walter; Kirsten Reschke; Thorsten Wiech; Johannes Weber; Klaus Rückauer; Pierre Francois Plouin; Vincent Darrouzet; Sophie Giraud; Charis Eng; Hartmut P H Neumann Journal: J Clin Endocrinol Metab Date: 2009-03-31 Impact factor: 5.958